Literature DB >> 10233837

Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis.

F Guadagni1, P Graziano, M Roselli, S Mariotti, P Bernard, P Sinibaldi-Vallebona, G Rasi, E Garaci.   

Abstract

Tumour liberated particles (TLP) have been proposed as a potential new serum tumor marker. In particular, a high percentage of patients with early stages of lung cancer scored positive for serum TLP, suggesting its possible role as a marker for early diagnosis of disease. The aim of the present study was to analyze the expression of TLP in the colorectal adenoma-carcinoma sequence in order to determine whether its expression correlates with the various stages of cancer transformation. TLP distribution was assessed by immunohistochemistry in normal, premalignant, and malignant colorectal lesions. Normal colonic mucosa and hyperplastic polyps showed no positive staining, whereas adenomas and adenocarcinomas reacted to anti-TLP serum. The percentage of positive tumor cells increased from adenomas with mild dysplasia to adenomas with severe dysplasia. Moreover, a supranuclear staining pattern was observed mainly in adenomas with mild dysplasia, whereas adenomas with severe dysplasia as well as adenocarcinomas showed a characteristic diffuse staining pattern and a strong staining intensity. Only a few cases of adenocarcinoma were found to be TLP-negative and all were poorly differentiated. Our results suggest that TLP antigen expression may be considered as a marker of epithelial atypia in the colorectal tract and as a potential target for new diagnostic and/or therapeutic approaches to human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233837      PMCID: PMC1866543          DOI: 10.1016/S0002-9440(10)65351-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.

Authors:  D Stramignoni; R Bowen; B F Atkinson; J Schlom
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

3.  Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.).

Authors:  J P Mach; P Jaeger; M M Bertholet; C H Ruegsegger; R M Loosli; J Pettavel
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

4.  Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen.

Authors:  E W Martin; M Cooperman; L C Carey; J P Minton
Journal:  J Surg Res       Date:  1980-05       Impact factor: 2.192

5.  Immunohistochemical characterization of tumor liberated particles (TLP) expression pattern in lung cancer.

Authors:  G Tarro; C Esposito; A Perna; P P Claudio; A Giordano
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

6.  Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer.

Authors:  H F Sears; M Herlyn; B Del Villano; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

7.  Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma.

Authors:  M Herlyn; H F Sears; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

8.  Pathology of colorectal adenomas: a colonoscopic survey.

Authors:  F Konishi; B C Morson
Journal:  J Clin Pathol       Date:  1982-08       Impact factor: 3.411

9.  Human tumor antigens inducing in vivo delayed hypersensitivity and in vitro mitogenic activity.

Authors:  G Tarro; A Pederzini; G Flaminio; S Maturo
Journal:  Oncology       Date:  1983       Impact factor: 2.935

10.  Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.

Authors:  J Lundy; A Thor; R Maenza; J Schlom; F Forouhar; M Testa; D Kufe
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.